Interestingly, IRF3 and BCL2L12 mRNA expression was significantly reduced in melanoma tumors with an IRF3/BCL2L12 promoter mutation as compared to tumors with a wild-type promoter region. The gene discussed is BCL2L12; the disease is melanoma.